Alveolar lipoproteinosis in lung allograft recipients

Human Pathology
S A Yousem

Abstract

Three cases of pulmonary alveolar proteinosis developing in lung allograft recipients are reported. In each case, repeated bouts of alveolar damage from harvest/reperfusion injury, rejection, and infection were observed before the development of intraalveolar accumulation of granular, periodic acid-Schiff-positive material in the allograft lungs. It is speculated that iatrogenic immunosuppression combined with defective clearance of alveolar material by alveolar macrophages created a milieu conducive to the accumulation of surfactant, lipoprotein, and fibrinous debris that was morphologically identical to alveolar proteinosis.

References

Dec 1, 1991·The American Review of Respiratory Disease·B J MilleronG M Akoun
Sep 1, 1989·Chest·R H Israel, C R Magnussen
Feb 1, 1967·Archives of Disease in Childhood·J C HaworthH Taylor
Mar 1, 1994·American Journal of Respiratory and Critical Care Medicine·C CordonnierJ F Bernaudin
Jun 5, 1958·The New England Journal of Medicine·S H ROSENA A LIEBOW

❮ Previous
Next ❯

Citations

Jul 14, 2010·Journal of General Internal Medicine·Shiwan K ShahGulshan Sharma
Jul 18, 2002·American Journal of Respiratory and Critical Care Medicine·John F Seymour, Jeffrey J Presneill
Aug 19, 2006·Respirology : Official Journal of the Asian Pacific Society of Respirology·Noel R WardwellLorraine B Ware
Dec 17, 2014·Revue des maladies respiratoires·S JouneauP Delaval
Sep 3, 2011·Pathology International·Michiya NishinoRichard L Kradin
Oct 6, 2012·Respirology : Official Journal of the Asian Pacific Society of Respirology·Steffen LethOle Hilberg
Aug 28, 2004·Clinics in Chest Medicine·Jeffrey J PresneillJohn F Seymour
May 16, 2002·Clinical Transplantation·Y ZhaoD E deMello
Feb 25, 2017·The European Respiratory Journal·Quentin PhilippotOlivier Brugière
Sep 8, 2004·Treatments in Respiratory Medicine·Saiprakash B VenkateshiahMani S Kavuru
May 5, 2020·Respirology : Official Journal of the Asian Pacific Society of Respirology·Stéphane JouneauMathieu Lederlin
Aug 19, 2006·Chronic Respiratory Disease·O C Ioachimescu, M S Kavuru
Feb 3, 2004·Critical Reviews in Computed Tomography·Maureen R Horton
Aug 20, 2021·Therapeutics and Clinical Risk Management·Hira IftikharAnupam Kumar

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.